Major histocompatibility complex markers in patients with nomifensine-induced immune hemolytic anemia.
To evaluate a possible role of major-histocompatibility-complex (MHC)-related immune-response genes for the selective production of drug-induced antibodies, HLA class I (ABC), class II (DR, DQ), class III (BF, C2, C4A, C4B) as well as glyoxalase-1 allotypes were investigated in 26 patients with nomifensine-induced immune hemolytic anemia. No statistically significant deviations of MHC antigen frequencies were noted. The possible implications of these findings are discussed.
Mueller-Eckhardt
G
G
Institute of Clinical Immunology and Blood Transfusion, University of Giessen, FRG.
Giers
G
G
Salama
A
A
Schendel
D J
DJ
Fass
G
G
Mueller-Eckhardt
C
C
D000328:Adult; D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000276:immunology*; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D006681:HLA-D Antigens / Q000032:analysis; D006649:Histocompatibility Antigens / Q000032:analysis*; D006801:Humans; D007791:Lactoylglutathione Lyase / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009627:Nomifensine / Q000009:adverse effects*; D010641:Phenotype
D006680:HLA Antigens; D006681:HLA-D Antigens; D006649:Histocompatibility Antigens; D009627:Nomifensine; D003165:Complement System Proteins; D007791:Lactoylglutathione Lyase